{"id":46123,"date":"2025-11-10T13:56:17","date_gmt":"2025-11-10T05:56:17","guid":{"rendered":"https:\/\/flcube.com\/?p=46123"},"modified":"2025-11-10T13:56:18","modified_gmt":"2025-11-10T05:56:18","slug":"aureka-biotechnologies-closes-multi%e2%80%91million%e2%80%91dollar-series-a-generative-antibody-platform-gains-5y-capital-qiming-backing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46123","title":{"rendered":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing"},"content":{"rendered":"\n

Aureka Biotechnologies<\/strong>, a pioneer in generative antibody drug development<\/strong>, announced today the successful close of its Series\u202fA financing round<\/strong> valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners<\/strong>, with continued participation from existing shareholder NRL Capital<\/strong> and additional investors including Agentic Ventures<\/strong>.<\/p>\n\n\n\n

Financing Highlights<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Round Size<\/strong><\/td>Multi\u2011million\u2011dollar (exact amount undisclosed)<\/td><\/tr>
Lead Investors<\/strong><\/td>5Y Capital, Qiming Venture Partners<\/td><\/tr>
Existing Backers<\/strong><\/td>NRL Capital<\/td><\/tr>
Other Participants<\/strong><\/td>Agentic Ventures, plus a syndicate of strategic angels<\/td><\/tr>
Use of Proceeds<\/strong><\/td>\u2022 Advance proprietary pipelines to key clinical milestones (PCC & pre\u2011IND)
\u2022 Accelerate construction of an integrated wet\u2011lab\/dry\u2011lab intelligent\u2011agent platform for antibody design
\u2022 Expand deep\u2011tech collaborations with global biopharma partners<\/td><\/tr>
Closing Date<\/strong><\/td>10\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Company Overview & Technology Platform<\/h2>\n\n\n\n
    \n
  • Mission:<\/strong> Build the world\u2019s first data\u2011driven, closed\u2011loop generative antibody discovery engine<\/strong> that unites high\u2011throughput single\u2011cell functional screening, yeast intracellular automated directed evolution, and a structure\u2011informed autonomous evolution design agent.<\/li>\n\n\n\n
  • Platform Architecture:<\/strong>
    Wet\u2011lab<\/strong> (high\u2011throughput functional assays, yeast evolution) \u2194 Dry\u2011lab<\/strong> (AI\u2011driven design, structural modeling) \u2192 Iterative feedback loop<\/strong> for rapid antibody optimization.<\/li>\n\n\n\n
  • Strategic Partnerships:<\/strong> Active joint projects with leading European and U.S. pharmaceutical companies<\/strong> targeting complex antigens and novel mechanisms, showcasing superior hit\u2011rates and development speed versus conventional platforms.<\/li>\n<\/ul>\n\n\n\n

    Pipeline Progress<\/h2>\n\n\n\n
    Therapeutic Area<\/th>Program Stage<\/th>Highlights<\/th><\/tr><\/thead>
    Autoimmune Diseases<\/strong><\/td>Pre\u2011Candidate Compound (PCC)<\/td>Lead antibody shows >80\u202f% target engagement in in\u2011vitro disease models.<\/td><\/tr>
    Metabolic Diseases<\/strong><\/td>Pre\u2011IND<\/td>IND\u2011enabling toxicology package on track; expected filing Q2\u202f2026.<\/td><\/tr>
    Additional Targets<\/strong><\/td>Early Discovery<\/td>Multiple high\u2011affinity binders generated via autonomous evolution; candidates entering PCC pipeline.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
      \n
    • Revenue Track:<\/strong> Over the past 24\u202fmonths, Aureka generated tens of millions of USD<\/strong> in commercial revenue from platform\u2011as\u2011a\u2011service agreements and early\u2011stage licensing deals.<\/li>\n\n\n\n
    • Future Outlook:<\/strong> Management is pursuing mid\u2011to\u2011long\u2011term co\u2011development and joint\u2011venture opportunities<\/strong> to expand the pipeline and broaden market reach.<\/li>\n<\/ul>\n\n\n\n

      Market Impact & Analyst Perspective<\/h2>\n\n\n\n
        \n
      • Capital Infusion:<\/strong> The Series\u202fA validates investor confidence in generative AI\u2011driven biologics<\/strong>, a segment projected to attract $5\u202fbn+<\/strong> in venture capital by 2027.<\/li>\n\n\n\n
      • Competitive Edge:<\/strong> Aureka\u2019s integrated wet\u2011lab\/dry\u2011lab loop<\/strong> offers a speed\u2011to\u2011clinic advantage<\/strong>\u2014potentially halving the typical antibody discovery timeline (12\u201318\u202fmonths vs. 24\u201330\u202fmonths).<\/li>\n\n\n\n
      • Strategic Fit:<\/strong> Partnerships with established pharma players could accelerate pipeline de\u2011risking<\/strong> and provide a fast\u2011track to global market entry<\/strong> for its autoimmune and metabolic candidates.<\/li>\n<\/ul>\n\n\n\n

        Forward\u2011Looking Statements<\/strong>
        This brief contains forward\u2011looking statements regarding financing terms, pipeline timelines, and commercial expectations for Aureka Biotechnologies. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and market adoption.<\/p>\n","protected":false},"excerpt":{"rendered":"

        Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of…<\/p>\n","protected":false},"author":1,"featured_media":46201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2705],"class_list":["post-46123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aureka-biotechnologies"],"yoast_head":"\nAureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46123\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing\" \/>\n<meta property=\"og:description\" content=\"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46123\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T05:56:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T05:56:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing\",\"datePublished\":\"2025-11-10T05:56:17+00:00\",\"dateModified\":\"2025-11-10T05:56:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1001.webp\",\"keywords\":[\"Aureka Biotechnologies\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46123#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46123\",\"name\":\"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1001.webp\",\"datePublished\":\"2025-11-10T05:56:17+00:00\",\"dateModified\":\"2025-11-10T05:56:18+00:00\",\"description\":\"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46123\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46123#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing - Insight, China's Pharmaceutical Industry","description":"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46123","og_locale":"en_US","og_type":"article","og_title":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing","og_description":"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.","og_url":"https:\/\/flcube.com\/?p=46123","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-10T05:56:17+00:00","article_modified_time":"2025-11-10T05:56:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46123#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46123"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing","datePublished":"2025-11-10T05:56:17+00:00","dateModified":"2025-11-10T05:56:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46123"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46123#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","keywords":["Aureka Biotechnologies"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46123#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46123","url":"https:\/\/flcube.com\/?p=46123","name":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46123#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46123#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","datePublished":"2025-11-10T05:56:17+00:00","dateModified":"2025-11-10T05:56:18+00:00","description":"Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series\u202fA financing round valued at several million dollars. The round was co\u2011led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46123#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46123"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46123#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","width":1080,"height":608,"caption":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46123#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aureka Biotechnologies Closes Multi\u2011Million\u2011Dollar Series\u202fA \u2013 Generative Antibody Platform Gains 5Y Capital & Qiming Backing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46123"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46123\/revisions"}],"predecessor-version":[{"id":46202,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46123\/revisions\/46202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46201"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}